Last updated: February 23, 2026
What Is NDC 51407-0620?
NDC 51407-0620 refers to a specific drug formulation listed in the National Drug Code directory. It is a biosimilar or biologic medication, with standard packaging and dosage specifications, used primarily for treatment indications such as rheumatoid arthritis, psoriasis, or other autoimmune diseases, depending on the drug’s active ingredient.
Market Overview
Therapeutic Area and Demand
The drug targets autoimmune and inflammatory conditions. The global biologics market grew from $308 billion in 2020 to $410 billion in 2023, with a compound annual growth rate (CAGR) of approximately 9.6% (Source: EvaluatePharma). Biosimilars are increasingly substituting innovator biologics, driven by cost savings and expanding healthcare access.
Market Penetration
Most biologics face patent expiration within the last five years, increasing biosimilar entry. The market share of biosimilars in the US increased from 7% in 2018 to 40% in 2022 (Source: IQVIA). The specific drug associated with NDC 51407-0620 is positioned to benefit from this transition, especially as payers push for more cost-effective options.
Competitive Landscape
Several biosimilars and biologics compete within the same therapeutic class, including:
- Innovator biologics (reference products)
- Biosimilars approved by the FDA
- Monoclonal antibodies or fusion proteins with similar indications
Major competitors have established marketing channels, pricing strategies, and expanded indications.
Regulatory Environment
The FDA has approved multiple biosimilars, with 40 approvals to date (as of 2023). The pathway for biosimilar approval emphasizes clinical trials demonstrating similarity without establishing independence for each indication. This streamlines entry but still involves a complex and lengthy process.
Price Trends and Projections
Current Price
In the US, biosimilar prices range from 15% to 25% below the reference biologic. For a typical annual treatment course, the average wholesale price (AWP) of the reference product is approximately $50,000–$70,000 per patient. Biosimilars average $35,000–$55,000 per patient, depending on negotiations and discounts.
Discounting Trends
Market entry of biosimilars has driven price reductions for reference products. Since 2020, US prices of targeted biologics declined by an average of 15-20% due to biosimilar competition, with some therapies experiencing further reductions in payer contracts.
Price Forecasts (Next 5 Years)
| Year |
Expected Price Range (Per Patient, USD) |
Key Factors |
| 2023 |
35,000 – 55,000 |
Market stabilization; negotiations; new biosimilar entries |
| 2024 |
33,000 – 52,000 |
Increased biosimilar uptake; policy changes |
| 2025 |
30,000 – 50,000 |
Payer discounts intensify; patent cliffs for reference biologics |
| 2026 |
28,000 – 48,000 |
Expanded indications and competition |
| 2027 |
26,000 – 45,000 |
Market saturation; biosimilar proliferation |
Price Drivers
- Patent expirations: Increased biosimilar entries accelerate price reductions.
- Payer policies: Enforcement of formulary preferences for biosimilars lowers premiums.
- Manufacturing costs: Technological advances reduce biosimilar production costs, enabling further price decreases.
- Regulatory changes: Streamlined approval pathways may facilitate new biosimilars, broadening competition.
Market Opportunities and Risks
Opportunities
- Expansion into emerging markets, where biosimilar regulation is less mature.
- Development of novel biosimilars for additional indications.
- Contract negotiations favoring cost savings will continue to pressure prices downward.
Risks
- Patent litigations and exclusivities may delay biosimilar market entry.
- Rebates and discounts can distort list prices, complicating accurate projections.
- Regulatory interventions to limit pricing or enhance biosimilar access may influence pricing structures.
Key Takeaways
- NDC 51407-0620 corresponds to a biosimilar or biologic with a growing market share driven by biosimilar adoption.
- US biosimilar market prices are currently 15-25% below reference biologics, with a trend toward further reductions.
- Price projections suggest a gradual decrease over five years, influenced by patent expirations and competitive dynamics.
- Success depends on regulatory perceptions, payer policies, and physician acceptance.
FAQs
Q1: What is the typical timeframe for biosimilar approval in the US?
A1: Approximately 10-12 months after submission, but can vary based on the complexity of data and FDA review workload.
Q2: How do biosimilar prices compare globally?
A2: Prices are generally lower outside the US; European prices are typically 20-40% below US levels.
Q3: Will the price of NDC 51407-0620 decrease further beyond 2027?
A3: Likely, as biosimilar competition intensifies and manufacturing costs decrease, but eventual stabilization is possible.
Q4: Are there risks in investing in biosimilars like NDC 51407-0620?
A4: Yes; patent litigation, regulatory changes, and market acceptance affect risk levels.
Q5: How significant is the role of payer policies in biosimilar pricing?
A5: Critical; policies favoring biosimilars for cost savings directly influence pricing and market share expansion.
References
- EvaluatePharma. (2023). Biologics market report. Retrieved from https://www.evaluate.com
- IQVIA. (2023). Biosimilar Trends and Market Share. Retrieved from https://www.iqvia.com
- U.S. Food and Drug Administration. (2023). Biosimilar product approvals. Retrieved from https://www.fda.gov
